PRMT3 is a type I arginine methyltransferase that catalyzes the methylation of arginine residues, first generating a monomethyl arginine intermediate, which is subsequently converted to asymmetric dimethylarginine.[37] PRMT3 has been extensively studied in oncology research, where it is recognized as a key regulator of metabolic reprogramming and gene expression in cancer.[38] However, its role in tauopathies remains largely understudied. Here, PRMT3 is linked to tauopathy.